Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Æó»ö¼º ´ã°üÁúȯÀÚÀÇ ÀåÅõ°ú¼ºÀÇ º¯È­ The changes of intestinal permeability in patients with obstructive biliary disease

´ëÇѳ»°úÇÐȸÁö 2004³â 67±Ç 6È£ p.589 ~ 596
±èÁ¤¿í, Àü¿ì±Ô, Àå¼¼°æ, ÀÌÁ¤¾È, ¹Úµ¿ÀÏ, Á¶¿ë±Õ, ¼ºÀΰæ, ¼ÕÁ¤ÀÏ, ±èº´ÀÍ, ±èÀºÁ¤, ½Å¸í¼÷,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁ¤¿í ( Kim Jeong-Wook ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Àü¿ì±Ô ( Jeon Woo-Kyu ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
Àå¼¼°æ ( Chang Se-Kyung ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÁ¤¾È ( Lee Jung-Ahn ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Úµ¿ÀÏ ( Park Dong-Il ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
Á¶¿ë±Õ ( Cho Yong-Kyun ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
¼ºÀΰæ ( Sung In-Kyung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
¼ÕÁ¤ÀÏ ( Sohn Chung-Il ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
±èº´ÀÍ ( Kim Byung-Ik ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ³»°ú
±èÀºÁ¤ ( Kim Eun-Jeong ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ÀÇÇבּ¸¼Ò
½Å¸í¼÷ ( Shin Myong-Suk ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø ÀÇÇבּ¸¼Ò

Abstract

¸ñÀû: Àå°üÀ庮 ÀÌ»óÀº Æó»ö¼º ´ã°üÁúȯ¿¡¼­ ¹ß»ýÇϸç Àå³»¼¼±ÕÀüÀ§³ª Àå°ü³»µ¶¼ÒÇ÷Áõ°ú °°Àº °¨¿°¼º ÇÕº´ÁõÀ» À¯¹ß ÇÑ´Ù. º» ¿¬±¸¿¡¼­´Â Æó»ö¼º ´ã°üÁúȯ¿¡¼­ Àå°üÀ庮 ÀÌ»ó°ú ÀÓ»ó¾ç»ó°úÀÇ °ü°è¸¦ ¾Ë¾Æº¸¾Ò´Ù.

¹æ¹ý: °Ç°­´ëÁ¶±º 18¸í, ¾ç¼ºÁúȯ¿¡ ÀÇÇÑ Æó»ö¼º ´ã°üÁúȯÀÚ 20¸í, ¾Ç¼ºÁúȯ¿¡ ÀÇÇÑ Æó»ö¼º ´ã°üÁúȯÀÚ 21¸í¿¡¼­ ÀåÅõ°ú¼º °Ë»ç¸¦ ½Ç½ÃÇÏ¿´À¸¸ç Áúȯ±º°£ Â÷ÀÌ¿Í °¢Á¾ ÀÓ»ó¾ç»ó°ú ¿¬°ü¼ºÀ» ºñ±³ÇÏ¿´´Ù. ÀåÅõ°ú¼º °Ë»ç´Â 51Cr-EDTA (51Cr-ethylenediaminetetraacetic acid)À» ÀÌ¿ëÇÏ¿© 24½Ã°£ ¼Òº¯¿¡¼­ÀÇ È¸¼öÀ²·Î ÃøÁ¤ÇÏ¿´´Ù.

°á°ú: ÀåÅõ°ú¼ºÀº Àå»ó´ëÁ¶±ºº¸´Ù Æó»ö¼º ´ã°üÁúȯÀÚ¿¡¼­ ³ô¾ÒÀ¸¸ç, ¾Ç¼ºÁúȯ¿¡ ÀÇÇÑ Æó»ö¼º ´ã°üÁúȯÀÚ¿¡¼­ ¾ç¼ºÁúȯÀÚº¸´Ù ³ô¾Ò´Ù. Æó»ö¼º ´ã°üÁúȯÀÚ¿¡¼­ Ȳ´ÞÀÌ ÀÖ¾úÀ» ¶§ ÀåÅõ°ú¼ºÀÌ ³ô¾ÒÀ¸¸ç(p<0.05), prothrombin time, activated partial thromboplastin timeÀÌ ÂªÀ»¼ö·Ï ÀåÅõ°ú¼ºÀÌ Áõ°¡ÇÏ¿´´Ù(p<0.05). ±×·¯³ª ¿°Áõ¹ÝÀÀ, ÃéÀå¿° À¯¹« ¹× Ç÷û ºô¸®·çºó ¼öÄ¡¸¦ Æ÷ÇÔÇÑ °£±â´É °Ë»çµî ´Ù¸¥ ÀÓ»ó¾ç»ó°ú´Â ¿¬°ü¼ºÀÌ ¾ø¾ú´Ù.

°á·Ð: Æó»ö¼º ´ã°üÁúȯ¿¡¼­ ÀåÅõ°ú¼ºÀÇ Áõ°¡´Â ¾Ç¼ºÁúȯ¿¡¼­ ¾ç¼ºÁúȯ¿¡ ÀÇÇÑ °æ¿ìº¸´Ù ³ôÀ¸¸ç Ç÷¾×ÀÀ°íÀÇ Ç×Áø¼Ò°ßÀº ÀåÅõ°ú¼º Áõ°¡ÀÇ ¿¹ÃøÀÎÀÚ·Î ÃßÁ¤µÈ´Ù.

Background: Gut barrier dysfunction occurs in experimental models and humans of obstructive biliary disease. This phenomenon promotes infectious complications including bacterial translocation and intestinal endotoxemia. The aims of this study were to examine correlations between gut barrier dysfunction and clinical characteristics in obstructive biliary disease.

Methods: The intestinal permeability were measured in 18 normal healthy controls, 20 patients with cholestasis caused by benign disease and 23 of them with cholestasis caused by malignant disease (common bile duct cancer; 16, pancreatic head cancer; 5) by measuring 24 hour urine excretion of 51Cr-EDTA (51Cr-ethylenediaminetetraacetic acid).

Results: The increase in intestinal permeability in malignant cholestatic disease was more higher than benign cholestatic disease (p<0.05). The increase in intestinal permeability showed significant correlation with shortening of prothrombin and activated partial thromboplastin time (p<0.05). No significant correlation was found between the increase in intestinal permeability and pancreatitis, inflammation or liver function including the changes of serum bilirubin level in patients with obstructive biliary disease.

Conclusion: The increase in intestinal permeability in obstructive biliary disease was more in malignant cholestatic disease than benign cholestatic disease. Activation of coagulation may be predictive factor for gut barrier dysfunction in patients with obstructive jaundice.(Korean J Med 67:589-596, 2004)

Å°¿öµå

Permeability; Intestine; Obstruction; bile duct; Blood coagulation

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS